Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine
| Autor: | Thomas S. Y. Chan, Harinder Gill, Yu-Yan Hwang, Carol Y. M. Cheung, Ian Y. H. Wong, Yok-Lam Kwong, Ian Y L Yeung |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Foscarnet
Ganciclovir Adult Male medicine.medical_specialty Population Congenital cytomegalovirus infection Retinitis Gastroenterology Antibodies Monoclonal Murine-Derived Internal medicine Medicine Humans education Aged education.field_of_study business.industry virus diseases Hematology General Medicine Middle Aged medicine.disease Fludarabine Immunology Cytomegalovirus Retinitis Rituximab Drug Therapy Combination Female Cytomegalovirus retinitis business Vidarabine medicine.drug |
| Zdroj: | Annals of hematology. 94(6) |
| ISSN: | 1432-0584 |
| Popis: | Cytomegalovirus (CMV) retinitis is exceptionally rare outside the clinical context of acquired immunodeficiency syndrome and organ allografting. In a population where seropositivity for past CMV infection exceeded 90 %, CMV retinitis was observed in five of 138 patients (3.6 %) receiving fludarabine-containing regimens together with rituximab, which was significantly more frequent than in 141 patients receiving fludarabine-containing regimens alone, where no case was observed (P = 0.029). Treatment of CMV retinitis comprised both intravitreal and systemic ganciclovir/foscarnet. Upon recovery, secondary retinal atrophy occurred in all patients, leading to blindness in 86 % of affected eyes. CMV retinitis is an important complication in patients receiving concomitant rituximab and fludarabine-containing regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink